Overview

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on you and your cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Bortezomib
Docetaxel